https://www.live-feeds.com/feed/glp-1-drugs-increase-rare-eye-stroke-linked-to-vision-loss-hundreds-of-lawsuits-allegeContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/glp-1-drugs-increase-rare-eye-stroke-linked-to-vision-loss-hundreds-of-lawsuits-allegehttps://www.live-feeds.com/feed/glp-1-drugs-increase-rare-eye-stroke-linked-to-vision-loss-hundreds-of-lawsuits-allege#u89427Tue, 29 Sep 2026 20:06:21 +0000Hundreds of lawsuits allege that GLP-1 receptor agonists, used for weight loss and diabetes treatment, increase the risk of a rare form of vision loss called nonarteritic anterior ischemic optic neuropathy (NAION). Plaintiffs claim they were not adequately warned about this potential risk. The scientific evidence is still evolving and not completely consistent. GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro, are at the center of the legal and medical debate.Why it mattersThe lawsuits have sparked a growing legal and medical debate over the safety of GLP-1-based medicines. NAION is a rare